These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 21395631)

  • 61. The effect of cysteamine bitartrate on adiponectin multimerization in non-alcoholic fatty liver disease and healthy subjects.
    Dohil R; Meyer L; Schmeltzer S; Cabrera BL; Lavine JE; Phillips SA
    J Pediatr; 2012 Oct; 161(4):639-45.e1. PubMed ID: 22633783
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Efficacy, safety and tolerability of vidofludimus in patients with inflammatory bowel disease: the ENTRANCE study.
    Herrlinger KR; Diculescu M; Fellermann K; Hartmann H; Howaldt S; Nikolov R; Petrov A; Reindl W; Otte JM; Stoynov S; Strauch U; Sturm A; Voiosu R; Ammendola A; Dietrich B; Hentsch B; Stange EF
    J Crohns Colitis; 2013 Sep; 7(8):636-43. PubMed ID: 23078909
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease.
    Pacifico L; Bonci E; Di Martino M; Versacci P; Andreoli G; Silvestri LM; Chiesa C
    Nutr Metab Cardiovasc Dis; 2015 Aug; 25(8):734-41. PubMed ID: 26026214
    [TBL] [Abstract][Full Text] [Related]  

  • 64. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.
    Pawlak M; Baugé E; Bourguet W; De Bosscher K; Lalloyer F; Tailleux A; Lebherz C; Lefebvre P; Staels B
    Hepatology; 2014 Nov; 60(5):1593-606. PubMed ID: 24995693
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease.
    Janssen RS; Mangoo-Karim R; Pergola PE; Girndt M; Namini H; Rahman S; Bennett SR; Heyward WL; Martin JT
    Vaccine; 2013 Nov; 31(46):5306-13. PubMed ID: 23727422
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Coated cysteamine and choline chloride could be potential feed additives to mitigate the harmful effects of fatty liver hemorrhagic syndrome in laying hens caused by high-energy low-protein diet.
    Yaqoob MU; Qi Y; Hou J; Zhe L; Zhu X; Wu P; Li Z; Wang M; Li Y; Yue M
    Poult Sci; 2024 Dec; 103(12):104296. PubMed ID: 39305615
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A Review on the Antimutagenic and Anticancer Effects of Cysteamine.
    Lee CM
    Adv Pharmacol Pharm Sci; 2023; 2023():2419444. PubMed ID: 37731680
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Metabolic Associated Fatty Liver Disease in Children-From Atomistic to Holistic.
    Mărginean CO; Meliț LE; Săsăran MO
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944682
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cystamine reduces vascular stiffness in Western diet-fed female mice.
    Ramirez-Perez FI; Cabral-Amador FJ; Whaley-Connell AT; Aroor AR; Morales-Quinones M; Woodford ML; Ghiarone T; Ferreira-Santos L; Jurrissen TJ; Manrique-Acevedo CM; Jia G; DeMarco VG; Padilla J; Martinez-Lemus LA; Lastra G
    Am J Physiol Heart Circ Physiol; 2022 Feb; 322(2):H167-H180. PubMed ID: 34890280
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.
    Di Ciaula A; Calamita G; Shanmugam H; Khalil M; Bonfrate L; Wang DQ; Baffy G; Portincasa P
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299321
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD).
    Grattagliano I; Di Ciaula A; Baj J; Molina-Molina E; Shanmugam H; Garruti G; Wang DQ; Portincasa P
    Methods Mol Biol; 2021; 2310():201-246. PubMed ID: 34096005
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?
    Di Ciaula A; Passarella S; Shanmugam H; Noviello M; Bonfrate L; Wang DQ; Portincasa P
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065331
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Evaluation of Quantitative Imaging Biomarkers for Early-phase Clinical Trials of Steatohepatitis in Adolescents.
    Goyal NP; Sawh MC; Ugalde-Nicalo P; Angeles JE; Proudfoot JA; Newton KP; Middleton MS; Sirlin CB; Schwimmer JB
    J Pediatr Gastroenterol Nutr; 2020 Jan; 70(1):99-105. PubMed ID: 31633654
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A randomized, controlled, crossover pilot study of losartan for pediatric nonalcoholic fatty liver disease.
    Vos MB; Jin R; Konomi JV; Cleeton R; Cruz J; Karpen S; Rodriguez DS; Frediani JK; McCracken C; Welsh J
    Pilot Feasibility Stud; 2018; 4():109. PubMed ID: 29992039
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter.
    Conjeevaram Selvakumar PK; Kabbany MN; Alkhouri N
    Paediatr Drugs; 2018 Aug; 20(4):315-329. PubMed ID: 29740791
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cysteamine, an Endogenous Aminothiol, and Cystamine, the Disulfide Product of Oxidation, Increase Pseudomonas aeruginosa Sensitivity to Reactive Oxygen and Nitrogen Species and Potentiate Therapeutic Antibiotics against Bacterial Infection.
    Fraser-Pitt DJ; Mercer DK; Smith D; Kowalczuk A; Robertson J; Lovie E; Perenyi P; Cole M; Doumith M; Hill RLR; Hopkins KL; Woodford N; O'Neil DA
    Infect Immun; 2018 Jun; 86(6):. PubMed ID: 29581193
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Current and future pharmacologic treatment of nonalcoholic steatohepatitis.
    Banini BA; Sanyal AJ
    Curr Opin Gastroenterol; 2017 May; 33(3):134-141. PubMed ID: 28346237
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
    Clemente MG; Mandato C; Poeta M; Vajro P
    World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
    [TBL] [Abstract][Full Text] [Related]  

  • 79. In Children With Nonalcoholic Fatty Liver Disease, Cysteamine Bitartrate Delayed Release Improves Liver Enzymes but Does Not Reduce Disease Activity Scores.
    Schwimmer JB; Lavine JE; Wilson LA; Neuschwander-Tetri BA; Xanthakos SA; Kohli R; Barlow SE; Vos MB; Karpen SJ; Molleston JP; Whitington PF; Rosenthal P; Jain AK; Murray KF; Brunt EM; Kleiner DE; Van Natta ML; Clark JM; Tonascia J; Doo E;
    Gastroenterology; 2016 Dec; 151(6):1141-1154.e9. PubMed ID: 27569726
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.